Metformin keeps CD8+ T cells active and moving in NASH-HCC immunotherapy
- PMID: 35714813
- DOI: 10.1016/j.jhep.2022.05.038
Metformin keeps CD8+ T cells active and moving in NASH-HCC immunotherapy
Conflict of interest statement
Conflict of interest AL has received research funding from Pfizer and Genentech and consulting fees from Astra Zeneca. PS declares no conflict of interest. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment on
-
Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD.J Hepatol. 2022 Sep;77(3):748-760. doi: 10.1016/j.jhep.2022.03.010. Epub 2022 Apr 1. J Hepatol. 2022. PMID: 35378172 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
